Tesamorelin Netherlands: regulatory status

In the Netherlands, tesamorelin has no marketing authorisation. The European Medicines Agency (EMA) never granted one: the applicant, Ferrer Internacional, S.A., withdrew the centralised marketing-authorisation application on 21 June 2012 after the Committee for Medicinal Products for Human Use (CHMP) signalled it could not reach a positive benefit-risk balance^[1]. Since then, no sponsor has re-filed for EU approval, and the situation has not changed as of July 2026.

That means Dutch patients and clinicians cannot access tesamorelin through the normal pharmacy route. What lawful access does exist runs through special-access channels that require a prescribing physician to take individual responsibility. This article explains what those channels are, why the EMA application failed, what the approved medicine looks like in the United States, and what anyone considering tesamorelin in the Netherlands actually needs to know before talking to a doctor.

Why the EMA application was withdrawn in 2012

The CHMP raised four distinct concerns before Ferrer Internacional withdrew^[1]:

First, the clinical meaningfulness question. Studies did show that tesamorelin reduced visceral abdominal fat in adults with HIV-associated lipodystrophy. The committee accepted that finding, but concluded that the reduction had not been shown to translate into actual health benefits for patients. Losing abdominal fat by scan measurement alone was not enough; the committee wanted evidence of outcomes that mattered to patients, such as reduced cardiovascular risk or improved quality of life.

Second, the IGF-1 safety concern. The CHMP noted that a considerable proportion of patients on tesamorelin showed elevated levels of insulin-like growth factor 1 (IGF-1). Elevated IGF-1 carries theoretical risks of cancer promotion and worsening of diabetic eye disease. The committee considered these risks insufficiently characterised, particularly given that the expected use would be long-term and no long-term safety data had been provided.

Third, the representativeness problem. Patients enrolled in the pivotal trials had higher body-mass indices and more abdominal fat than typical European HIV patients. The committee was not confident the trial results would generalise to the EU population as it actually exists.

Fourth, the diagnostic difficulty. The CHMP noted that differentiating HIV-associated lipodystrophy from ordinary excess abdominal fat would be difficult in clinical practice, creating a risk of off-label prescribing to patients for whom the evidence did not apply.

The applicant withdrew rather than submit a rebuttal. No sponsor has filed a fresh EMA application for tesamorelin in any EU indication since.

What the approved medicine looks like in the US

In the United States, the FDA approved tesamorelin in 2010 as Egrifta, then as the more concentrated formulation Egrifta SV. The approved indication is narrow: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The label is explicit that tesamorelin is not indicated for general weight management^[3]. Both Egrifta SV and Egrifta WR are prescription-only, dispensed through licensed US pharmacies, and manufactured by Theratechnologies^[4].

The evidence base for that indication is reasonably solid. A 2026 meta-analysis of five randomised controlled trials reported a significant reduction in visceral adipose tissue (mean difference: 27.71 cm²) versus placebo, alongside modest increases in lean body mass and reductions in hepatic fat^[5]. Adverse events in those trials included arthralgia, myalgia, paresthesia, and injection-site reactions. Glucose intolerance was observed in roughly 5% of treated patients versus 1% on placebo, and elevated IGF-1 was present in 47% of patients at 26 weeks. These safety signals are exactly what drove the CHMP concerns in 2012.

None of this evidence applies to off-label uses. The trials were conducted in HIV-positive adults with clinically confirmed lipodystrophy, on the labelled dose, for that specific endpoint. Body-composition, anti-ageing, and longevity discussions that invoke tesamorelin are drawing on the mechanism, not the trial programme.

What lawful access looks like in the Netherlands

Because tesamorelin has no marketing authorisation in the Netherlands or anywhere in the EU, it cannot be dispensed through the standard prescription route. The only lawful pathway is the unlicensed-medicine or named-patient route, which operates under national law. Under this route, a Dutch prescribing physician can request an unlicensed import of tesamorelin for a specific named patient, provided the physician takes clinical responsibility for the prescription and documents a clinical justification for why no authorised alternative is suitable.

The EMA framework for compassionate use, established under Article 83 of Regulation (EC) No 726/2004, allows member states to set their own rules for granting access to unauthorised medicines^[2]. The Netherlands implements this through the College ter Beoordeling van Geneesmiddelen (CBG-MEB), which is the Dutch medicines evaluation board. The practical consequence for tesamorelin is that a specialist physician (typically an HIV clinician or endocrinologist) who determines a patient has HIV-associated lipodystrophy and no adequate authorised alternative could, in principle, initiate a named-patient import request.

In practice, this route is rarely used. The named-patient pathway is designed for seriously ill patients with no other options; it is not a general access mechanism, and the clinical justification must be well-documented and specific. General or online sale of tesamorelin to consumers in the Netherlands is not lawful, and customs authorities may detain shipments.

The off-label landscape in the Netherlands

Tesamorelin appears in online and clinic discussions around body composition and growth-hormone optimisation across Europe, including the Netherlands. The context is almost always off-label: the approved indication (HIV-associated lipodystrophy) is narrow, and most people considering tesamorelin do not have that diagnosis.

From a regulatory standpoint, this matters in two ways. First, there is no authorised tesamorelin product to prescribe off-label: a Dutch physician prescribing tesamorelin off-label is always working through the unlicensed-medicine route, regardless of the indication. Second, the evidence base for off-label use is essentially absent. The published trial programme covers one indication, one population, and one dose schedule. Use outside those parameters is not supported by trials, and the long-term safety picture in non-HIV populations, including the IGF-1 cancer risk concern, has not been characterised.

If you are considering tesamorelin for any purpose, the first conversation belongs with a physician who can assess your specific situation and advise on whether any lawful route exists. We do not recommend or facilitate the purchase of unlicensed peptides. For the cross-country regulatory picture, see the tesamorelin peptide page and the broader Netherlands regulation hub.

What has not changed since 2012

The short answer is: nothing of regulatory substance in the EU. The CHMP concerns from 2012 have not been resolved by new trial data submitted to the EMA. Theratechnologies has not sought EU approval in the fourteen years since the withdrawal. The company's strategic focus remains the US market, where the approved indication (HIV-associated lipodystrophy) is maintained. There is no public indication that a new EMA submission is planned.

The 2026 meta-analysis does provide an updated evidence summary for the approved HIV-lipodystrophy indication, but it is a synthesis of existing trials, not new Phase 3 data. It does not change the regulatory picture in the Netherlands or the EU.

Medical disclaimer

This article is for educational and journalistic purposes only and does not constitute medical advice. Tesamorelin is classified as a prescription medicine in the United States and has no marketing authorisation in the Netherlands or the EU. Always consult a qualified healthcare professional before considering any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product. Regulatory disclaimer: this page reflects our understanding of the regulatory status as of July 2026. Regulations change. Verify with the official regulator before making any decision.